Bicycle Therapeutics Ltd (BCYC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $222.90M
Last updated: Nov 17, 2026 at 4:15 PM ET
Bicycle Therapeutics Ltd (BCYC) Statistics
Bicycle Therapeutics (BCYC) has a market cap of $222.90M. Revenue grew 194.75% over the last 12 months from the 12 months before. It kept -169.75% of revenue as net income over the last 12 months.
Total Valuation
| Market Cap | $222.90M |
|---|---|
| Latest price (Nov 17, 2026) | $3.20 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.7x and 0.4x. Its year-end P/S ranged from 6.8x to 132.3x from 2019 to 2025.
| P/S Ratio | 2.7x |
|---|---|
| Forward P/S | 5.9x |
| P/B Ratio | 0.4x |
Price Statistics
The stock is down 50.62% over 52 weeks and trades 12.57% below its 50-day average.
| Beta (1Y) | 1.69 |
|---|---|
| 52-Week Change | -50.62% |
| 1-Month Change | -9.48% |
| 3-Month Change | -22.71% |
| 6-Month Change | -26.44% |
| 5-Year Change | -92.88% |
| Total Return (1Y) | -50.62% |
| Total Return (3Y CAGR) | -38.63% |
| Total Return (5Y CAGR) | -44.08% |
| Return vs SPY (1Y) | -62.10% |
| Max Drawdown (1Y) | -57.71% |
| Max Drawdown (3Y) | -88.44% |
| Sharpe Ratio (1Y) | -1.40 |
| Correlation with SPY (1Y) | 0.46 |
| 50-Day Average | $3.66 |
| 200-Day Average | $4.37 |
| 52-Week Range | $3.07 to $7.83 |
| RSI (14 Days) | 36.1 |
| Average Volume (20 Days) | 407.89K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 12.09x current liabilities.
| Current Ratio | 12.09x |
|---|---|
| Quick Ratio | 12.09x |
| Interest Coverage | -715.98x |
Returns and Efficiency
Return on equity is -28.06% over the last 12 months, against a 5-year average of -33.37%.
| Return on Equity (ROE) | -28.06% |
|---|---|
| Return on Assets (ROA) | -25.00% |
| Return on Capital Employed (ROCE) | -26.57% |
| ROE (5Y Average) | -33.37% |
| ROA (5Y Average) | -23.98% |
| ROIC (5Y Average) | -30.55% |
| Asset Turnover | 0.13x |
| Receivables Turnover | 1.67x |
Scores
BCYC has an Altman Z-Score of 0.03, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.03 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $83.53M over the last 12 months.
| Revenue | $83.53M |
|---|---|
| Revenue Growth (YoY) | +194.75% |
| Gross Profit | $83.53M |
| Operating Income | -$158.28M |
| Pretax Income | -$139.09M |
| Net Income | -$141.79M |
| EBITDA | -$134.29M |
| EBIT | -$138.90M |
| Reported EPS (TTM) | -$2.03 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 89.09% of the $567.18M in total assets.
| Cash and Equivalents | $469.93M |
|---|---|
| Working Capital | $493.10M |
| Shareholder Equity | $505.28M |
| Total Assets | $567.18M |
| Total Liabilities | $61.90M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.86M of capital spending, operating cash flow left -$176.70M of free cash flow.
| Operating Cash Flow | -$174.85M |
|---|---|
| Capital Expenditures | $1.86M |
| Free Cash Flow | -$176.70M |
| FCF Per Share | -$3.49 |
| Depreciation and Amortization | $4.61M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -189.50%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -189.50% |
| Pretax Margin | -166.52% |
| Net Margin | -169.75% |
| EBITDA Margin | -160.78% |
| EBIT Margin | -166.29% |
| FCF Margin | -211.55% |
Growth
Revenue grew 71.21% a year over 3 years.
| Revenue Growth (3Y CAGR) | +71.21% |
|---|---|
| Revenue Growth (5Y CAGR) | +47.52% |
Dividends and Yields
BCYC does not pay a dividend. Its free cash flow yield is -78.91%.
| FCF Yield | -78.91% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 6 similar companies, BCYC has the lowest P/S.
P/S RatioPeer median 11.4x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -51.34%
| P/S Ratio | 2.7x vs 11.4x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +194.75% vs -51.34% median |
Analyst Forecast
Consensus estimates put revenue growth at 18.42% a year over the next 5 fiscal years.
| Revenue Growth Forecast (5Y CAGR) | +18.42% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About BCYC
What is BCYC's market cap?
Bicycle Therapeutics has a market cap of $222.90M.
How many shares of BCYC are outstanding?
Bicycle Therapeutics has 69.98M shares outstanding. The count is up 0.98% from a year earlier.
Does BCYC pay a dividend?
No. Bicycle Therapeutics does not pay a dividend.
BCYC pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors